Compare Recursion Pharmaceuticals Inc (RXRX) vs Sea Limited (SE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Sea Limited — how do they compare? Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B), while Sea Limited trades at $95.25 (market cap $56.89B). The key difference: Sea Limited is far larger — about 26.6× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Sea Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 23 Days and Sea Limited for 102 Days on average.
| RXRX | SE | |
|---|---|---|
Market Cap | $2.14B | $56.89B |
Volume | 30,789,535 | 5,359,457 |
Sector | Health | Consumer Cyclical |
52-Week High | $6.79 | $188.00 |
52-Week Low | $2.84 | $78.16 |
Typical Hold Time | 23 Days | 102 Days |
Enterprise Value | $1.66B | $51.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.36, up 2.11% today, with technical indicators showing a bullish trend. The company reported Q3 2026 revenue of $54 million but continues to post significant losses with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche are expanding its AI-driven drug pipeline, though the stock faces high short interest and substantial cash burn from operations.
The outlook remains speculative given persistent losses and high valuation multiples (P/S 37.14), but analyst consensus leans positive with 40% buy ratings. Key risks include execution on drug development timelines and dependence on financing activities to fund operations. Upside potential hinges on successful clinical milestones from its expanding pipeline.
Sea Limited (SE) trades at $92.89, down 1.87% on the day, as technical indicators signal bearish momentum with the stock testing key support levels. Fundamentally, the company shows strong revenue growth with 2025 revenue reaching $22.94 billion and net income of $1.58 billion, though recent Q4 2025 earnings missed expectations. Analyst sentiment remains overwhelmingly positive with 31 buy ratings and a consensus price target of $153.67, representing significant upside potential from current levels.
The investment case hinges on Sea's continued e-commerce and fintech expansion, with Shopee's growth and Monee's profit potential driving long-term value. However, risks include competitive pressures, margin compression concerns, and recent insider selling activity. The current price decline presents a potential buying opportunity for investors believing in Sea's Southeast Asia growth story, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
